We believe our research work will help identify new successful treatment options and benefit patients, as well as healthcare providers.

R&D projects are carried out both in Abano Terme’s laboratories and at the Research Unit in Noto (Sicily). The latter’s activities focus on the optimization of biopolymer production (i.e., enzymes, recombinant proteins and polysaccharides), using non-pathogenic host strains of bacteria.

High on the company’s list of priorities is the study of hyaluronic acid, a molecule that at Fidia means tradition, innovation, excellence: approximately 20,000 patients have been involved in over 180 international clinical studies investigating intra-articular hyaluronic acid, whereas more than 20 million patients have been treated with intra-articular hyaluronic acid-based products so far.

Extensive clinical experience

- 35% Discovery phase
- 28% Preclinical phase
- 37% Clinical phase

Farmaceutici S.p.A.

Find out our Corporate Website:

Go to the website

Fidia’s other websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Middle East product portfolio focalizes primarily on therapeutic areas such as joint healthcare and tissue repair.

Fidia Pharma Middle East is focused on providing consumers with innovative products that offer quality, safety and performance and exploring innovative channel strategies to access customers and consumers, such as healthcare e-commerce.